OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedAetnaPolicy 0004

Obstructive Sleep Apnea in Adults

Customize your policy alerts

Sign up for Aetna Policy 0004 alerts

Get alerted when Policy 0004 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines Aetna's medical necessity, diagnostic, treatment, device, accessory, surgical, and investigational coverage policies for obstructive sleep apnea (OSA) in adults (age ≥18). Applies to Aetna-covered members and providers submitting claims or prior authorizations.

Policy Summary

PayerAetna

PolicyObstructive Sleep Apnea in Adults

Policy CodePolicy 0004

Change TypeMaterial update to hypoglossal nerve stimulation eligibility and BMI limits

Effective DateAug 10, 1995

Last ReviewMar 13, 2024

Next Review DateJan 9, 2025

Key ActionObtain prior authorization documenting PSG-based AHI/RDI and evidence of CPAP trial or intolerance before approving PAP devices or hypoglossal nerve stimulation.

SourceLink

POLICY UPDATE CHANGES

FDA expanded UAS AHI eligibility from 20-65 to 15-65 events/hour in March 2017 and later to ≤100 events/hour with BMI limit increased to 40.

15+AHI auto PAP threshold

5-14AHI symptomatic range

15-100UAS AHI eligibility

BMI <40UAS BMI limit

5-yearPAP device RUL

14.6%Surgery complication rate

Coverage Criteria and Medical Necessity Rules

Attended Full-Channel Nocturnal Polysomnography (NPSG) — Medical Necessity

Attended Type I NPSG performed in a healthcare facility is medically necessary for diagnosis when used as part of a comprehensive sleep evaluation and one or more listed indications are met.

Indications for attended NPSG: Member has at least one of the following comorbid medical conditions that degrade accuracy of portable monitoring: moderate-to-severe pulmonary disease (e.g., COPD/asthma with nocturnal O2 use or daytime hypercapnia), neuromuscular disease, stroke with residual respiratory effects, epilepsy, congestive heart failure (NYHA III/IV or LVEF <45%), pulmonary hypertension (mean PAP >25 mm Hg), chronic opioid use, or super obesity (BMI >45 or obesity hypoventilation criteria)

Comorbid sleep disorder indications: Member has one or more comorbid sleep disorders such as periodic limb movement disorder, atypical parasomnias, severe insomnia, narcolepsy, or suspected central/complex sleep-disordered breathing that require in-lab evaluation

Inadequate/failed home testing or low pretest probability: Negative, inconclusive, or technically inadequate portable (home) monitoring; or low pretest probability where home testing is unlikely to be accurate (for example normal BMI <30, Mallampati 1–2, absence of snoring, normal neck circumference), or lack of patient mobility/dexterity to use portable monitoring

Unattended (Home) Sleep Studies — Medical Necessity

Unattended home sleep studies are medically necessary when used as part of a comprehensive sleep evaluation and use one of the specified device types.

Covered home device types: Type II device (≥7 channels) OR Type III device (≥4 channels incl. ventilation/airflow, heart rate/ECG, oximetry) OR Type IV(A) device measuring airflow plus ≥2 other channels and providing AHI OR devices measuring ≥3 channels including pulse oximetry, actigraphy, and peripheral arterial tone (e.g., Watch-PAT)

Appropriate use conditions: Home testing must be performed in conjunction with a comprehensive sleep evaluation and is inappropriate for patients with significant comorbid medical conditions that degrade accuracy of unattended studies (e.g., moderate-severe pulmonary disease, neuromuscular disease, congestive heart failure) or suspected other sleep disorders; a single-night recording is generally adequate, but if negative/inconclusive an attended NPSG is required

Positive Airway Pressure (PAP) Devices — Medical Necessity

CPAP, APAP, AutoPAP and variants are medically necessary durable medical equipment when diagnostic testing and reporting meet specified numeric and technical criteria.

PAP coverage numeric criteria: (1) AHI or RDI ≥ 15 events/hour with minimum 30 events; OR (2) AHI or RDI ≥5 and <15 events/hour with minimum 10 events AND at least one qualifying finding: history of stroke, documented hypertension (SBP>140 or DBP>90), ischemic heart disease, documented impaired cognition/mood/insomnia, excessive daytime sleepiness (Epworth >10), OR >20 desaturation episodes (<85%) during full-night study or any episode <70% O2 saturation

Study adequacy and scoring: Sleep study used to justify PAP must be based on ≥2 hours continuous recorded sleep (or equivalent event count) with AHI/RDI calculated per policy definitions; indices that include non-AHI disturbances (e.g., RERAs counted as AHI) or that count only REM are not acceptable

Alternate PAP Modalities and Indications

Bilevel and other alternate PAP modalities and oral pressure appliances are medically necessary in specified circumstances.

BiPAP/alternate PAP criteria: BiPAP (without backup rate), BiPAP with pressure relief, DPAP, VPAP are medically necessary for members intolerant of or in whom CPAP/AutoPAP is ineffective; documentation must show proper mask fitting/interface, that lower pressure settings were attempted and failed to control symptoms or reduce AHI/RDI

OPAP (oral pressure appliance): Oral pressure appliance (OPAP) is medically necessary only on an exception basis for members unable to tolerate standard nasal/face mask due to facial discomfort, sinus pain, or claustrophobia

Accessories, Supplies, and Replacement

Lists medically necessary accessories, supplies, and conditions for device replacement and their reasonable useful lifetime.

Covered accessories and supplies: Chinstrap; disposable or non-disposable filters; full face mask; headgear; heated or non-heated humidifier; nasal interface; oral interface; replacement cushions/pillows; replacement interfaces for full face mask; tubing for humidifier are medically necessary when the member meets PAP criteria

Replacement and RUL: Replacement of PAP devices and oral appliances is medically necessary at the end of a 5-year reasonable useful lifetime or earlier if the member’s clinical condition changes; replacement due to misuse or abuse is not covered

Oral Appliances — Medical Necessity

Mandibular advancement and tongue-retaining oral appliances are medically necessary when diagnostic testing and clinical conditions meet stated criteria.

Oral appliance numeric criteria: (1) AHI or RDI ≥15 events/hour with minimum 30 events; OR (2) AHI or RDI ≥5 and <15 events/hour with minimum 10 events AND one qualifying finding (history of stroke, documented hypertension, ischemic heart disease, impaired cognition/mood/insomnia, excessive daytime sleepiness [Epworth >10 or MSLT <6], OR >20 desaturation episodes <85% or any desaturation <70%); OR (3) AHI/RDI >30 when member cannot tolerate PAP or PAP is contraindicated

Replacement of oral appliances is medically necessary at end of 5-year RUL or earlier for clinical change; replacement due to misuse/abuse not covered

Hypoglossal Nerve Neurostimulation — Medical Necessity

FDA‑approved hypoglossal nerve stimulation (upper-airway stimulation, UAS) is medically necessary only when all listed criteria are met.

UAS criteria: Member age ≥18; BMI <40 kg/m2; polysomnography within 24 months of consultation; predominantly obstructive events (central + mixed <25% of total AHI); AHI 15–100 events/hour; at least one month of CPAP monitoring documenting CPAP failure (AHI >15 despite CPAP) or CPAP intolerance (<4 hrs/night on ≥5 nights/week); absence of complete concentric velopharyngeal collapse on DISE; and no other anatomical findings that would compromise device performance (e.g., tonsil size 3–4)

DISE

Drug-induced sleep endoscopy (DISE) is used selectively to evaluate surgical candidacy and device suitability.

DISE use for UAS candidacy: DISE is medically necessary to evaluate appropriateness of FDA‑approved hypoglossal nerve stimulation when multiple levels of obstruction are suspected and UAS criteria are being applied; DISE is experimental/investigational for other indications

DISE documentation: When used for UAS evaluation, DISE findings should be documented (VOTE classification/video) and demonstrate absence of complete concentric velopharyngeal collapse to meet selection criteria

Surgical Treatments — Medical Necessity

Describes surgical options considered medically necessary and conditions that must be met.

Medically necessary surgeries: Pharyngeal/lingual tonsillectomy (when hypertrophied tonsils compromise airway), adenoidectomy for significant nasopharyngeal obstruction, nasal surgeries (valve surgery, polypectomy, septoplasty, turbinectomy) for nasal obstruction with CPAP intolerance, tongue base reduction procedures for hypopharyngeal obstruction, palatopharyngoplasty (UPPP) for CPAP-intolerant or inadequately responsive patients meeting CPAP criteria, and tracheostomy for the most severe OSA not manageable by other interventions

CPAP trial prior to UPPP: Medical records must document attempted CPAP or AutoPAP (with mask/pressure adjustments) and reasons for intolerance or inadequate response before considering palatopharyngoplasty (UPPP)

Palatopharyngoplasty (UPPP) — Medical Necessity

Covered when ALL of the following are met

UPPP coverage prerequisites: Member meets criteria for CPAP/AutoPAP but has had an inadequate response or is intolerant to CPAP/AutoPAP despite adjustments to pressure and mask as appropriate

Intolerance includes claustrophobia, pressure intolerance, inability to sleep with device, interface intolerance, nasal irritation, or repeated unintentional removal of CPAP during sleep

Documentation: Medical records must document that the member has attempted CPAP or AutoPAP before considering surgery

Tracheostomy — Medical Necessity

Covered when ALL of the following are met

Tracheostomy for severe OSA: Member has the most severe OSA not manageable by other interventions

Requests are subject to medical review; follow Medicare DME MAC rules for tracheostomy supplies

Diagnostic testing criteria

Covered diagnostic approaches and when they are appropriate

Diagnostic testing for OSA: Polysomnography (attended in-lab NPSG, Type I) is the standard diagnostic test; technically adequate home sleep apnea testing (Type II–IV devices meeting sensor/channel requirements) may be used in uncomplicated adult patients presenting with increased risk for moderate-to-severe OSA; home testing must be accompanied by comprehensive sleep evaluation and follow-up; home testing is inappropriate for patients with significant comorbidities or suspected other sleep disorderssee device type definitions

Study technical adequacy: Sleep study reports must include AHI or RDI calculated from at least 2 hours of continuous recorded sleep (or equivalent event count); estimates based on shorter recordings must meet minimum event counts; AHI must include all sleep stages and be scored per policy definitions≥2 hours or equivalent event count

Treatment coverage and sequencing

Treatment hierarchy and coverage notes

First-line therapy: CPAP is first-line therapy for OSA; a CPAP trial period (e.g., up to 3 months) with compliance monitoring is typical; bilevel and other PAP modalities are second-line for CPAP-intolerant patients or those with comorbid respiratory disorders

Alternative therapies covered when selection criteria met: Oral appliances, select surgeries (e.g., UPPP, tonsillectomy when tonsils compromise airway, jaw realignment for failures), tracheostomy for unmanageable severe cases, and implantable neurostimulators are covered when specific selection criteria and documentation (e.g., prior CPAP trial/intolerance, PSG metrics) are met

Therapy selection and indications

Treatment approach and typical indications described in the literature excerpted here:

CPAP as first-line: CPAP remains the initial treatment for most adults with OSA; alternatives are generally reserved for those intolerant of or failing CPAP

Second-line alternatives: Bilevel modes (BiPAP, DPAP, VPAP), oral appliances, and surgery are options for patients intolerant of or who fail CPAP; ASV (bilevel with backup rate) is considered investigational for OSA

Oral appliance considerations: Oral mandibular advancement devices are effective alternatives but generally less effective than CPAP and usually reserved for CPAP-intolerant patients; evidence supports both prefabricated and custom appliances

Surgical indications: Surgery (UPPP, tonsillectomy, jaw realignment, tongue-base procedures) may be considered for selected patients who fail or cannot tolerate CPAP; surgical choice depends on anatomic site(s) of obstruction

Coverage considerations for implants, surgery, and EPAP devices

Evidence indicates coverage decisions should consider both demonstrated benefit and limitations; where randomized controlled trials show limited or mixed benefit, treatment may be considered only for selected patients after conservative therapy fails.

General selection for implants/surgery/EPAP: Adult patients considered for palatal implants, tongue-base devices, transpalatal surgery, or EPAP/Provent devices should have objective diagnosis by PSG and documented prior trial and intolerance or failure of CPAP when the device/surgery is proposed as an alternativePSG-documented OSA; prior CPAP trial when applicable

Palatal implants evidence: Evidence is insufficient to establish long-term efficacy for palatal implants (e.g., Pillar); randomized trials show limited overall effectiveness

Nasal/EPAP devices: Randomized and long-term studies report reductions in AHI and ESS with EPAP in selected patients with good adherence; consider for CPAP-intolerant patients after demonstration of objective benefit

Non-CPAP device coverage considerations

Evidence-based coverage considerations for non-CPAP devices (EPAP, OPT, positional devices):

EPAP device considerations: Randomized and long-term studies demonstrate EPAP can reduce AHI and ESS with high adherence in subsets of patients; consider as alternative for CPAP-intolerant patients when PSG documents objective improvement

Oral Pressure Therapy (OPT): OPT (Winx) showed clinically significant responses in an identifiable subgroup in short-term trials; consider only when a PSG trial demonstrates response and the patient cannot tolerate CPAP

Positional therapy: Positional devices may benefit patients with strictly positional OSA but are generally inferior to CPAP and show variable long-term compliance; consider when non-supine AHI and device-specific criteria are metDevice-specific limits (e.g., non-supine AHI <20 for some devices)

Modalities not recommended as primary therapy:

UAS selection and response criteria (from trials)

Reported trial inclusion/exclusion and responder criteria for upper-airway stimulation (UAS):

UAS trial selection notes: Early trials selected patients with moderate-to-severe OSA who failed/intolerant of CPAP; responders had BMI ≤32 and baseline AHI ≤50 and lacked complete concentric palatal collapse—these selection criteria informed later device labeling

OPT responder definition

OPT (Winx) trial responder definition used in study:

OPT clinical responder: Treatment AHI ≤10 events/hour AND ≤50% of control-night AHI (composite responder definition)AHI ≤10 and ≤50% of control

UAS (Hypoglossal Nerve Stimulation) — Medical Necessity Criteria

Covered when ALL of the following are met (per FDA labeling and expert statements):

UAS candidate selection (policy): Age meets device labeling (adults ≥18; historically ≥22 with later expansions), baseline PSG demonstrating AHI within current FDA-indicated range, predominance of obstructive events (<25% central/mixed), documented CPAP failure or intolerance, favorable endoscopic airway assessment with no complete concentric velopharyngeal collapse on DISE, absence of contraindicating anatomical findings (e.g., large tonsils), and ability to operate device programmer and no contraindications to MRI per device labelingSee device labeling and thresholds

Partial Epiglottidectomy — Candidate Criteria

Surgical epiglottidectomy/partial epiglottidectomy:

Epiglottidectomy candidate criteria: Considered for selected patients with OSA attributable to abnormal epiglottis or epiglottic prolapse causing hypopharyngeal obstruction, identified on endoscopic evaluation and when other targeted site surgeries are appropriate; evidence is limited and documentation of site-specific obstruction is required

Surgical/device evidence summary

Evidence-based considerations for surgical/device interventions (as reported):

Context for considering surgery or device: Reported series commonly included adults with moderate-to-severe OSA who failed or were intolerant of PAP and often had multi-level obstruction; patient selection, PSG metrics, and anatomic assessment were central to reported outcomes

Reported procedural outcomes: Outcomes across studies are variable (examples: midline glossectomy + epiglottidectomy and TORS series report varying cure/success rates); these evidence summaries inform cautious, selected use rather than broad coverage

Device evidence note: Some devices (e.g., Silent Partner) have FDA 510(k) clearance but lack evidence of superiority over standard oral appliances; document device model and regulatory status when requesting coverage

Evidence summaries (informational)

Evidence summaries and outcome observations (informational):

Lateral pharyngoplasty evidence: Small comparative studies report possible incremental benefit when added to UPPP in selected moderate OSA patients; overall evidence limited

Mandibular distraction osteogenesis (MDO): Systematic review reports promising results in selected adults with retrognathia but RCTs and standard definitions of success are lacking

RCMP utility: Remotely controlled mandibular positioner (RCMP) single-night titration predicted success with mandibular advancement oral appliances in several studies, and may be useful for selection

DISE utility and limitations: DISE can identify collapse patterns correlated with PSG severity (VOTE classification) but is subjective with inter-rater variability; used to guide surgical planning and UAS evaluation

Positional therapy (device) candidacy

Guidance derived from summarized evidence

Positional therapy candidacy: Patient has positional OSA (supine-predominant) AND meets device-specific criteria (e.g., non-supine AHI <20 for devices cleared with that limit) OR documented CPAP intolerance; positional therapy may be reasonable when CPAP adherence is poor but is generally inferior to CPAP for AHI reductionnon-supine AHI <20 for some devices

Surgical therapy — tongue base reduction

Surgical tongue-base reduction considerations

Tongue base reduction candidacy/outcomes: Robotic and endoscopic midline glossectomy and other tongue-base reduction procedures may improve AHI, ESS, and O2 nadir in selected patients; greater volume removed associated with higher success in some series; consider after multidisciplinary assessment and PSG documentation

Respiratory muscle therapy

Non-device conservative therapies

Respiratory/oropharyngeal muscle therapy: Respiratory muscle and oropharyngeal (myofunctional) exercises may reduce AHI and improve ESS and snoring versus controls based on RCTs with heterogeneous methods; consider as adjunctive therapy though evidence quality is low

Evidence summaries — biomarkers and emerging treatments

Summary statements about biomarker findings and emerging treatments (informational):

Biomarker associations: Meta-analyses report higher IL-6, TNF-α, CRP/hs‑CRP, MDA and other markers in OSA versus controls with some correlation to severity; biomarkers are investigational for routine diagnosis or management

Emerging therapies: EASE, MARPE, palatal expansion, Slow Wave DS8, TES/TENS, ansa cervicalis stimulation and other novel interventions have preliminary/small-study evidence and are considered investigational or limited evidence for routine coverage; HNS (UAS) has stronger evidence for selected patients

Evidence summaries (no explicit coverage rules in excerpt)

Evidence summaries and device indications — informational (no explicit coverage rules in excerpt):

CRP and inflammatory markers: Meta-analyses show higher hs-CRP/CRP, IL-8, leptin and other inflammatory markers in OSA with some correlation to AHI/severity; clinical utility as diagnostic biomarkers is not established

Daytime neuromuscular tongue stimulation (eXciteOSA): eXciteOSA is FDA-cleared for adults with mild OSA (AHI 5–15) and snoring based on trials showing reductions in snoring and mean AHI in mild OSA subgroups; evidence supports device labeling-based useAHI 5–15

BDNF/MCP-1 findings: BDNF peripheral levels do not reliably differ in OSA or change with CPAP (no diagnostic utility); MCP-1 and other markers show associations with OSA severity but are investigational

Indications for Obstructive Sleep Apnea Testing

Testing for OSA is considered medically necessary when clinical features of moderate to severe OSA are present as follows:

Primary entry: Excessive daytime sleepiness (EDS) AND one of: BMI >30 OR excessive sleepiness while driving OR loud/intense snoring

Alternative entry - ESS: Epworth Sleepiness Scale (ESS) score ≥10ESS >= 10

Alternative entry - witnessed events: Witnessed nocturnal apnea, choking, and/or gasping

Medically necessary indications for OSA testing

Testing for OSA is considered medically necessary for individuals who present with clinical features suggestive of moderate to severe OSA as evidenced by:

EDS plus features: Excessive daytime sleepiness (EDS) and ONE of: BMI >30; excessive sleepiness while driving; loud/intense snoring

ESS criterion: Epworth Sleepiness Scale (ESS) score of 10 or greaterESS >= 10

Witnessed nocturnal events: Witnessed nocturnal apnea, choking and/or gasping

Treatment of isolated snoring in the absence of objectively documented obstructive sleep apnea is not considered medically necessary. The policy specifies that oral appliances for snoring only (for example, Slow Wave DS8, Snore Guard) are not medically necessary, because snoring alone is not regarded as a disease warranting covered treatment.

Certain items associated with positive airway pressure therapy are classified as convenience items and are not medically necessary. Examples called out in the policy include bed pillows, batteries, and DC adapters for PAP devices, which are excluded from coverage as non‑medical convenience items.

Orthodontic therapy such as braces, brackets, and wires is excluded from medical coverage under standard Aetna medical plans even when provided in the context of OSA care. Dental rehabilitation and routine orthodontic procedures should be pursued under dental benefits where applicable; they are not covered as medical treatment for OSA.

Palatopharyngoplasty (including UPPP and variant palatal procedures) is addressed specifically: it is considered medically necessary for OSA only when the member meets CPAP/AutoPAP criteria and has an inadequate response to or is intolerant of CPAP despite appropriate adjustments, with documentation of prior CPAP attempts. Palatopharyngoplasty is considered experimental or unproven for non‑OSA indications (e.g., UARS) and other uses outside the described OSA criteria.

The policy lists multiple procedures and devices as not covered for OSA indications. Notable examples include LAUP (S2080/42160), palatal implants (Pillar system; C9727), somnoplasty/coblation codes (30801, 30802, 41530), certain tongue suspension procedures (41512), positional device codes (E0190, E0530), and several neuromuscular stimulation/oral device codes (E0490–E0493, K1027). These items are designated as not covered or not medically necessary for the indications enumerated in the policy.

The American Academy of Sleep Medicine's Standards of Practice Committee reviewed the evidence and does not recommend laser‑assisted uvulopalatoplasty (LAUP) for treatment of sleep‑related breathing disorders. The policy aligns with that guidance and does not support LAUP for OSA management.

Adaptive servo‑ventilation (ASV) — i.e., bilevel positive airway pressure devices with a backup rate feature — is considered investigational for treatment of OSA. Consistent with DME MAC guidance cited in the policy, ASV (bilevel with backup rate) is not an established therapy for OSA and may be denied for that indication.

Palatal (soft‑palate) implants (for example, the Pillar system) lack sufficient reliable evidence of long‑term efficacy for OSA. Health technology assessments (CADTH, NICE) concluded that evidence is inadequate to support routine use; the policy therefore treats palatal implants as unsupported by reliable evidence for treatment of OSA.

Specific palatal implant devices (Pillar™ palatal implants and similar soft‑palate implant systems) are not supported as established effective treatments for OSA based on the available assessments and randomized data. The policy identifies these soft‑palate implant procedures (HCPCS/CPT/HCPCS entries such as C9727) as lacking sufficient evidence and not recommended for routine OSA management.

The policy identifies various pharmacologic and device‑based approaches that are not recommended as effective primary treatments for OSA. Examples include systemic drugs, nasal dilators, and apnea‑triggered electrical muscle stimulation. Task force and systematic review conclusions indicate these methods do not have sufficient evidence to support routine use for OSA.

Trials of upper‑airway stimulation (hypoglossal nerve stimulation) excluded certain patients; the policy notes typical study exclusion criteria including BMI > 32 kg/m2, neuromuscular disease, hypoglossal‑nerve palsy, significant pulmonary disease, advanced cardiac disease, recent myocardial infarction or serious arrhythmias, persistent uncontrolled hypertension, active psychiatric disease, and coexisting non‑respiratory sleep disorders. Devices implanted outside these selection criteria may not reflect the populations studied.

A documented finding of complete concentric velopharyngeal collapse on screening sleep endoscopy (DISE) is an exclusion for hypoglossal nerve upper‑airway stimulation. The policy also lists other anatomic or functional contraindications (e.g., large tonsils, need for MRI incompatible with the device, inability to operate the programmer) that preclude UAS candidacy.

A recent UpToDate surgical review does not list several emerging procedures as standard therapeutic options for adult OSA. Specifically, techniques such as endoscopically‑assisted surgical expansion (EASE) and surgical palatal expansion (including MARPE) are not described as established management options in the cited UpToDate summaries, indicating limited endorsement in mainstream surgical guidance.

Mandibular distraction osteogenesis (MDO) is not included in UpToDate’s adult OSA management reviews, reflecting limited endorsement as a standard treatment option for adult OSA in current clinical reviews and guidelines.

Positional therapy devices that have received FDA 510(k) clearance are indicated only for patients meeting device‑specific criteria. For example, the Lunoa System is indicated for adult positional OSA when the non‑supine AHI is less than 20; device labeling and selection criteria must be met for appropriate use.

UpToDate surgical reviews do not mention some emerging procedures such as EASE or palatal expansion as standard management options for adult OSA. Because these techniques are discussed primarily in small retrospective series, the policy treats them as emerging with limited evidence and not established in mainstream guideline reviews.

The eXciteOSA trials and FDA clearance excluded patients with higher BMI and more severe OSA. Reported trial exclusion criteria included BMI > 35 kg/m2, AHI > 15, symptomatic nasal pathology, significant tonsillar hypertrophy (grade ≥3), pacemakers or implanted electrical devices, prior oral surgery for snoring, relevant facial skeletal abnormalities, and significant oral disease. These selection limits inform appropriate candidate selection.

NightLase laser therapy may be ineffective when the anatomic site of obstruction is not in the oropharynx (for example, nasal or hyoid‑level obstruction). Trial authors emphasize careful patient selection and note that long‑term effectiveness requires further study; therefore clinical caution is recommended regarding NightLase for OSA.

Monitoring devices are classified by minimum parameter requirements. The policy requires devices meet Type I–III or Type IV(A) technical standards for diagnostic sufficiency; devices that do not meet these minimum parameter requirements (e.g., Type IV(B) single‑ or dual‑bioparameter recordings such as overnight oximetry alone) are considered less adequate for diagnostic confirmation of moderate to severe OSA.

The policy identifies several diagnostic procedures and techniques as experimental, investigational, or unproven for OSA evaluation. Examples include acoustic pharyngometry, actigraphy when used alone, diagnostic audio recording with or without pulse oximetry, daytime nap polysomnography, natural sleep endoscopy for routine evaluation, and other listed novel or unvalidated diagnostic approaches.

The Zzoma positional device is specifically identified as not medically necessary for OSA because available evidence did not demonstrate superiority over other interventions for maintaining non‑supine sleep position.

The policy summarizes a group of devices and procedures that are not medically necessary or are considered investigational for OSA indications. This includes positional devices like Zzoma, palatal implants (Pillar), somnoplasty/coblation, certain oral stimulation systems (E0490–E0493), NightLase and several other emerging or device‑specific therapies listed in the not‑medically‑necessary and experimental sections.

The policy designates several CPT/HCPCS codes and device categories as not covered or not medically necessary when billed for OSA indications. Examples include positional device codes (E0190, E0530), palatal implant code (C9727), neuromuscular stimulation device codes (E0490–E0493), and LAUP (S2080). Providers should reference the policy's coding lists when submitting claims because these items may trigger denials if billed for the OSA indications described.

Procedures performed solely to treat snoring (without objective evidence of OSA) are not medically necessary. The policy aligns with AASM guidance that LAUP is not recommended for sleep‑related breathing disorders, and Aetna does not cover uvulectomy/uvu loplasty when performed only for snoring because snoring alone is not associated with functional impairment warranting medical coverage.

Codes and Coding Guidance

Covered CPT Codes (when selection criteria are met)CPTCovered

70350	Cephalogram, orthodontic.
70355	Orthopantogram.
95800	Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis and sleep time.
95801	Minimum of heart rate, oxygen saturation, and respiratory analysis.
95806	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, unattended.
95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist.
95808	Polysomnography; sleep staging with 1-3 additional parameters, attended.
95810	Polysomnography; age 6+, sleep staging with 4 or more additional parameters, attended.
95811	Polysomnography with initiation of CPAP or bilevel ventilation, attended.
21120	Genioplasty; augmentation.

1–10 of 22

1/3

Covered HCPCS Codes (when selection criteria are met)HCPCSCovered

G0398	Home sleep study test with type II portable monitor, unattended; minimum of 7 channels.
G0399	Home sleep test with type III portable monitor, unattended; minimum of 4 channels.
G0400	Home sleep test with type IV portable monitor, unattended; minimum of 3 channels.
A4604	Tubing with integrated heating element for use with positive airway pressure device.
A7027	Combination oral/nasal mask, used with CPAP device.
E0601	Continuous positive airway pressure (CPAP) device.
E0470	Respiratory assist device, bi-level pressure capability, without back-up rate feature.
E0472	Respiratory assist device, bi-level pressure capability, with back-up rate feature, invasive interface.
E0485	Oral device/appliance used to reduce upper airway collapsibility, prefabricated.
E0486	Oral device/appliance used to reduce upper airway collapsibility, custom fabricated.

1–10 of 15

1/2

ICD-10 Codes (covered when selection criteria are met / not covered lists)ICD-10

G47.33	Obstructive sleep apnea (adult) (pediatric).
G47.01	Organic & non-organic sleep disorders (range listed).
R06.83	Snoring.
I27.0	Primary pulmonary hypertension.
Z13.83	Encounter for screening for respiratory disorder NEC (asymptomatic OSA) (listed as not covered).

Additional diagnostic CPT Codes referencedCPT

95803	Actigraphy testing, recording, analysis, interpretation, and report.
95805	Multiple sleep latency or maintenance of wakefulness testing.
94760	Noninvasive ear or pulse oximetry for oxygen saturation; single determination.
94761	Multiple determinations (e.g., during exercise).
94762	Continuous overnight monitoring (separate procedure).

Codes for hypoglossal nerve neurostimulation and related devicesCPTCovered

64582	Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array.
64584	Removal of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array.
95970	Electronic analysis of implanted neurostimulator pulse generator/transmitter without programming.

Neurostimulation/related covered codes when selection criteria metmixedCovered

95977	with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional
C1767	Generator, neurostimulator (implantable), nonrechargeable
C1778	Lead, neurostimulator (implantable)
C1787	Patient programmer, neurostimulator
L8680	Implantable neurostimulator electrode, each
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension
G47.33	Obstructive sleep apnea (adult) (pediatric)

Surgical CPT codes (covered when selection criteria met / some not covered)CPT

42145	Palatopharyngoplasty (e.g., uvulopalatopharyngoplasty, uvulopharyngoplasty)
42140	Uvulectomy, excision of uvula
42160	Destruction of lesion, palate or uvula (thermal, cryo or chemical)
42820	Tonsillectomy and adenoidectomy; younger than age 12
42821	Tonsillectomy and adenoidectomy; age 12 or over
42825	Tonsillectomy, primary or secondary; younger than age 12
42826	Tonsillectomy, primary or secondary; age 12 or over
42831	Adenoidectomy, primary age 12 or over
42836	Adenoidectomy, secondary; age 12 or over
30801	Cautery and/or ablation, mucosa of inferior turbinates, superficial

1–10 of 21

1/3

Nasal surgery CPT/HCPCS and related ICD-10 codesmixed

30110-30115	Excision, nasal polyp(s)
30130	Excision inferior turbinate, partial or complete, any method
30140	Submucous resection inferior turbinate, partial or complete
31237-31240	Nasal/sinus endoscopy
C9749	Repair of nasal vestibular lateral wall stenosis with implant(s)
J33.0-J33.9	Nasal polyp
J34.3	Hypertrophy of nasal turbinates
R09.81	Nasal congestion

Various devices/therapies and associated HCPCS/CPT/ICD listings (many noted as not covered for OSA indications)mixedNot Covered

S2080	Laser-assisted uvulopalatoplasty (LAUP)
E0190	Positioning cushion/pillow/wedge (Zzoma positional device)
C9727	Insertion of implants into the soft palate; minimum of three implants (Pillar)
E0530	Electronic positional obstructive sleep apnea treatment, with sensor
K1027	Oral device/appliance used to reduce upper airway collapsibility, custom fabricated
E0720	TENS device, two lead
E0730	TENS device, four or more leads
G0237	Therapeutic procedure to increase strength or endurance of respiratory muscles, 15 minutes
G0238	Therapeutic procedures to improve respiratory function, other than G0237
G0239	Therapeutic procedures to improve respiratory function, two or more individuals

1–10 of 11

1/2

Neuromuscular stimulation / oral device codes (listed as not covered for OSA indications)mixedNot Covered

E0490	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle
E0491	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, 90-day supply
E0492	Power source and control electronics unit for oral device/appliance controlled by phone application
E0493	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application, 90-day supply
K1027	Oral device/appliance used to reduce upper airway collapsibility, custom fabricated
R06.83	Snoring

ICD-10 codes explicitly listed as not covered for CPB indicationsICD-10Not Covered

G47.00-G47.09	Organic and non-organic sleep disorders
G47.30	Sleep apnea, unspecified
G47.31	Primary central sleep apnea
G47.32	High altitude periodic breathing
G47.34	Idiopathic sleep related nonobstructive alveolar hypoventilation
G47.35	Congenital central alveolar hypoventilation syndrome
G47.36	Sleep related hypoventilation in conditions classified elsewhere
G47.37	Central sleep apnea in conditions classified elsewhere
G47.39	Other sleep apnea
R06.81	Apnea, not elsewhere classified

1–10 of 11

1/2

FDA clearances referencedmixed

510(k)

FDA 510(k) clearance (SleepStrip, Encore, Zzoma positional device referenced)

Device regulatory statusmixed

FDA 510(k)

Silent Partner device cleared via 510(k)

Device regulatory codes/statusmixed

FDA 510(k)

Regulatory clearance status for the Lunoa System

Procedure codes referenced in studiesCPT

21685

Hyoid myotomy and suspension (reported in the retrospective study)

AHI / RDI thresholds (summary for coding decisions)

Primary numeric thresholdAHI or RDI ≥15 events/hour with minimum 30 events

Symptomatic/comorbid lower-range thresholdAHI or RDI ≥5 and <15 events/hour with minimum 10 events plus at least one qualifying condition (eg, stroke, hypertension, ischemic heart disease, impaired cognition/mood/insomnia, Epworth >10, or >20 desaturation episodes <85% or any desaturation <70%)

Minimum recording requirementAHI/RDI must be calculated from at least 2 hours of continuous recorded sleep (or equivalent event count per policy)

Provider Actions, Prior Authorization & Documentation

Prior Authorization

PAP Device Coverage Criteria

PAP device coverage criteria: Positive airway pressure (PAP) devices (CPAP, APAP, APAP with pressure relief, and BiPAP without backup rate when indicated) are considered medically necessary DME when objective sleep testing meets policy AHI/RDI thresholds and scoring rules (AHI/RDI ≥15 events/hr with ≥30 events, or AHI/RDI 5–14.9 events/hr with ≥10 events plus qualifying comorbidity or symptoms). Home sleep test minimum recording and event-count rules apply; indexes that include non‑AHI/RDI events (eg, RERAs, leg movement) are not acceptable for PAP authorization. Replacement is covered at end of a 5‑year reasonable useful lifetime or sooner for clinical change; replacements due to misuse or abuse are not covered.

PAP types covered: CPAP, CPAP with pressure relief, APAP, APAP with pressure relief; BiPAP/DPAP/VPAP when CPAP/APAP intolerant or ineffective and criteria documented
Sleep test requirements: minimum recording rules, event count thresholds, AHI vs RDI definitions and acceptable device types (Type I–IV, WatchPAT)
Replacement rules: 5‑year RUL; earlier replacement only for clinical change; misuse/abuse excluded

Note

Background, Rationale and Evidence Summaries

Background: Obstructive sleep apnea (OSA) is diagnosed using attended in‑lab polysomnography (Type I) or, when appropriate, technically adequate home sleep testing (Types II–IV, including devices such as Watch‑PAT) as part of a comprehensive clinical evaluation. Treatment options range from positive airway pressure therapies (CPAP, APAP, BiPAP), oral appliances, site‑directed surgeries, to FDA‑approved hypoglossal nerve stimulation for selected candidates. Device selection and diagnostic testing are guided by device type definitions and clinical risk factors.

Definitions and Glossary

Apnea definition

Apnea definitionCessation of airflow for at least 10 seconds

Source contextPolicy definitions note apnea counts in AHI calculations and scoring rules

Implication for scoringApneas count toward AHI when scored per policy AASM definitions

Hypopnea definition

Hypopnea definitionAn abnormal respiratory event lasting ≥10 seconds with ≥30% reduction in thoraco‑abdominal movement or airflow and ≥4% oxygen desaturation

Scoring implicationHypopneas are counted with apneas to compute AHI in Type I/II studies per policy note

Use in RDI/AHI

Policy Revision History

2017-03-01FDA label expansion

FDA expanded upper-airway stimulation (UAS) AHI eligibility by lowering the minimum AHI from 20 events/hour to 15 events/hour.

2023-06-01FDA label expansionLatest

FDA expanded UAS indications to increase the upper AHI limit to ≤100 events/hour and raised the recommended BMI upper limit to 40 kg/m2.

Policy Summary

PayerAetna

PolicyObstructive Sleep Apnea in Adults

Policy CodePolicy 0004

Change TypeMaterial update to hypoglossal nerve stimulation eligibility and BMI limits

Effective DateAug 10, 1995

Last ReviewMar 13, 2024

Next Review DateJan 9, 2025

Key ActionObtain prior authorization documenting PSG-based AHI/RDI and evidence of CPAP trial or intolerance before approving PAP devices or hypoglossal nerve stimulation.

SourceLink

On This Page

Tongue-base and transpalatal surgeries: Outcomes for tongue-base and transpalatal surgeries are variable; device failures/adverse events reported for some devices—consider these options only in selected patients after multidisciplinary evaluation and PSG/anatomic assessment

Therapies including drugs, nasal dilators, apnea-triggered muscle stimulation, and several single-site surgeries lack sufficient evidence for routine primary use

Apnea-Hypopnea Index (AHI) thresholds for coverage

Coverage AHI cutoff for automatic PAP coverageAHI or RDI ≥15 events/hour with minimum 30 events

Lower AHI range eligible with comorbidity/symptomsAHI/RDI 5–14 events/hour with at least 10 events AND ≥1 qualifying comorbidity or excessive daytime sleepiness (Epworth >10)

Event-count requirement for short recordingsIf <2 hours of sleep recorded, total events must equal the number that would be required in a 2‑hour period (eg, >30 events without symptoms or >10 events with symptoms)

Split-night study diagnostic portion guidance

Minimum diagnostic portionDiagnostic portion of a split‑night study should be at least 2 hours duration

Preferred sleep time for titrationMinimum of 3 hours sleep is preferred to adequately titrate CPAP after split‑night diagnostic portion

Recording/analysis paritySplit‑night studies require recording and analysis of the same parameters as a standard diagnostic NPSG

Obesity risk threshold (BMI) referenced

Obesity defined as risk factorBody mass index (BMI) ≥30 considered supportive risk factor for OSA

Other risk markersLarge neck circumference, male sex, post‑menopausal female, and hypertension also increase OSA risk

Use in testing indication logicExcessive daytime sleepiness plus ≥2 of loud snoring, witnessed apnea/gasping, or diagnosed hypertension indicates increased risk

AHI thresholds for response definitions

Complete response (treatment success)AHI < 5 events/hour (complete response)

Good responseAHI < 10 events/hour

Partial response≥50% reduction in AHI but AHI remains >5 events/hour

AHI numeric labeling history (FDA labeled ranges)

Original FDA UAS AHI labelHistorically AHI 20–65 events/hour (initial FDA labeling)

2017 FDA expansionAHI lower limit expanded to 15 events/hour (March 2017)

2023 FDA expansionUpper AHI limit expanded to ≤100 events/hour with concomitant BMI upper limit increases (June 2023)

Body Mass Index (BMI) limits referenced for UAS

Initial trial BMI selectionEarly UAS trials often used BMI ≤32 kg/m2 as an inclusion criterion

Current FDA recommended BMI limitFDA labeling expanded recommended upper BMI limit to 40 kg/m2 (2023)

Policy criterion for UASPolicy requires BMI <40 kg/m2 for medical necessity of hypoglossal neurostimulation

Response definition (post-op RDI threshold example)

Example post-op RDI response thresholdStudy-defined responder: post‑operative respiratory disturbance index (RDI) below 20

Study contextMidline glossectomy with epiglottidectomy study (n=12) used RDI <20 to define response

Interpretation cautionSmall study size limits generalizability of this example threshold

Surgical cure and success criteria (AHI-based) examples

Surgical cure definitionCure: AHI < 5 events/hour (traditional surgical cure criterion)

Surgical success definitionSuccess: AHI < 20 events/hour combined with >50% reduction from baseline

Example multi‑level resultsTORS + palatal surgery series reported cure in 35% and success in 55% (small series)

Lunoa non-supine AHI indication

Device-labeled non-supine AHI limit (Lunoa)Lunoa System indicated for adults with positional OSA and non‑supine AHI < 20

FunctionDevice records position and provides vibro‑tactile feedback to avoid supine sleep

Evidence noteInsufficient evidence regarding overall effectiveness despite FDA 510(k) clearance

Epworth Sleepiness Scale threshold

ESS abnormal thresholdEpworth Sleepiness Scale (ESS) total score >10 considered abnormal

Use in testing/coverageESS >10 is an indication to justify OSA testing per policy appendix

Scoring methodESS is sum of eight item scores (0–3 each); total >10 abnormal

ULTepap device service-life labeling note

ULTepap cartridge service lifeULTepap bi‑resistance cartridges are warrantied for a 3‑year expected service life

Device classificationULTepap is a reusable single‑patient EPAP device cleared by FDA (510[k], Jan 24, 2020)

Components includedSystem includes headgear and appropriately sized nasal pillow; accessories similar to current products

Epworth Sleepiness Scale numeric threshold repeat

ESS numeric abnormal repeatEpworth Sleepiness Scale total score greater than 10 is considered abnormal

Clinical documentation expectationProviders should document ESS score when ordering OSA testing (policy appendix)

Role in selectionESS used alongside other clinical features (EDS, BMI, witnessed apneas) to justify testing

BMI threshold noted as supportive for testing

BMI supportive threshold for testingBMI >30 cited as a supportive clinical feature for OSA testing (included in EDS + one criterion list)

Risk contextBMI ≥30 is among factors increasing pretest probability for moderate‑to‑severe OSA

Policy useEDS plus BMI >30 can satisfy criteria to pursue diagnostic testing (Appendix)

Prior Authorization Not Stated Explicitly Here (Operational Note)

Prior authorization: The policy text does not stipulate a single, universal prior authorization (PA) requirement for all procedures/devices in this section. Providers should follow payer-specific PA procedures where listed elsewhere. Where implants, neurostimulators, and some surgeries are subject to utilization review or medical necessity review, prior authorization is recommended to confirm selection criteria are met before implantation or device dispensing.

No single PA statement in this excerpt — follow payer PA processes
PA is recommended for implants and device-based therapies to confirm criteria and avoid denials

Prior Authorization

Prior Authorization Recommended for Implants and Implantable Neurostimulators

Prior authorization recommended for implants/devices: For implanted neurostimulators (hypoglossal nerve stimulators/UAS), implanted leads/generators, and newer implantable or procedural devices (eg, tongue‑suspension anchors, palatal implants, glossectomy‑related implants), obtain prior authorization or pre‑service medical review to ensure FDA labeling, selection criteria, and documentation (PSG, DISE, BMI limits, prior CPAP trial) are met.

HCPCS/LT codes for implantable neurostimulator components require selection criteria to be met (see coding section)
Confirm FDA approved indication and up‑to‑date BMI/AHI limits prior to implantation

Documentation Required

Device Clearance and FDA Labeling — Operational Reminder

Device clearance note: Many devices described (CPAP, home sleep monitors, oral appliances, Lunoa, eXciteOSA, Inspire UAS, Lunoa positional systems, Elevo, ULTepap) have FDA 510(k) clearance or specific FDA approvals; clearance status does not by itself establish clinical effectiveness for all indications. Verify device-specific FDA labeling and approved indications when evaluating coverage.

510(k) clearance common for many home sleep and oral devices
Some devices (Inspire UAS, Lunoa, eXciteOSA) have FDA approvals/clearances with specific labeled indications and contraindications

Prior Authorization

Prior Authorization: Match UAS Trial/Label Selection Criteria

Prior authorization to match trial selection criteria for UAS: Prior to UAS implantation, ensure documentation aligns with trial/label selection criteria: age, BMI threshold, PSG results within required timeframe, predominance of obstructive events, prior CPAP failure/intolerance documented, and DISE demonstrating absence of complete concentric collapse.

PSG within timeframe (eg, within 24 months of first consultation historically; check current device labeling)
AHI/ODI ranges per device labeling (device-specific: e.g., Inspire expanded to AHI up to 100 and BMI up to 40 in recent FDA updates)
Document CPAP failure (AHI > device‑specified threshold on CPAP) or CPAP intolerance (<4 hrs/night on ≥5 nights/week)

Prior Authorization

Prior Authorization: Confirm FDA Labeling and Selection Criteria

Prior authorization: confirm FDA labeling and selection criteria — for hypoglossal nerve stimulation and other device implants, prior authorization (or medical review) should confirm current FDA‑cleared/approved AHI and BMI ranges, contraindications, MRI labeling, and any device‑specific requirements (eg, requirement for DISE).

Confirm current FDA AHI and BMI thresholds (updates have occurred)
Confirm MRI labeling and any device contraindications prior to implant

Documentation Required

Oral Appliance Devices and FDA Status — Documentation Expectations

Oral appliance devices and FDA status: Oral appliances (mandibular advancement devices, tongue retainers, Silent Partner, Snore Guard, Slow Wave DS8) may be FDA‑cleared (510(k)) or marketed as Class II devices. Oral appliances are generally considered a second‑line alternative to CPAP for patients intolerant of CPAP. Document device type (custom vs prefabricated) and clinical rationale for use.

Oral appliances effective for mild‑to‑moderate OSA; less reliable than CPAP
Document prior CPAP intolerance when using oral appliances as alternative

Prior Authorization

DISE Required for UAS Candidacy Evaluation

DISE required for UAS candidacy evaluation: Drug‑induced sleep endoscopy (DISE) is required per FDA‑approved UAS selection criteria to document absence of complete concentric collapse at the velum; DISE may be considered investigational for other indications. DISE findings (VOTE classification) should be documented in the record.

DISE must document absence of complete concentric velopharyngeal collapse for UAS candidacy
Record DISE using VOTE classification where possible

Prior Authorization

Positional Therapy Devices — Prior Authorization Considerations

Positional therapy device prior authorization: For newer positional therapy systems (eg, Lunoa, Sleep Position Trainer, Lunoa System), verify FDA clearance/indications and consider prior authorization when the device is being requested as an alternative to CPAP; ensure positional OSA criteria are documented (non‑supine AHI <20 and positional dependence).

Lunoa cleared for positional OSA with non‑supine AHI <20 (510k) — document positional dependence
Consider PA to confirm that positional therapy is appropriate and less‑invasive options attempted or contraindicated

Prior Authorization

eXciteOSA — Prior Authorization Considerations

eXciteOSA: prior authorization considerations: eXciteOSA is FDA‑cleared for daytime neuromuscular tongue stimulation in mild OSA and snoring. When requesting coverage, document indication (AHI 5–15 for mild OSA), patient age, exclusions (BMI limits, dental conditions, pacemaker/implanted electrical device), and expected treatment course (20 minutes/day for 6 weeks, then maintenance). Consider PA to confirm candidacy and that alternatives were considered.

FDA clearance limited to adults with mild OSA and snoring (AHI 5–15)
Document WatchPAT or equivalent baseline AHI and inclusion/exclusion criteria met

Billing Rule

PAP Supplies — Quantities and Intervals

PAP supplies quantities and intervals: Follow the policy’s usual medically necessary quantities and replacement intervals for PAP supplies (eg, tubing, masks, cushions, filters, headgear, chinstraps). Ensure supply requests align with the listed frequencies (monthly, quarterly, semiannual) and do not exceed policy limits.

Examples: tubing/heated tubing — 1 per 3 months; full face mask — 1 per 3 months; cushion replacements — typically 2 per month; headgear — 1 per 6 months; filters — disposable 2 per month

Denial Risk

Invalid AHI/RDI Basis — Potential Denial

Invalid AHI/RDI basis — denial risk: Requests based on an AHI/RDI calculated from indices that include non‑AHI events (eg, leg movements, RERAs not separated) or derived from too short a recording or insufficient event count are not acceptable and may be denied. Ensure sleep study meets minimum recording duration and event‑count rules per policy.

AHI/RDI must be calculated per policy definitions and minimum recording/event counts met
Projections from short recordings or indices counting REM‑only events are unacceptable

Denial Risk

Replacement Exclusion — Coverage Limitation

Replacement exclusion: Replacement of PAP devices required because of misuse or abuse is not covered. Replacement coverage is limited to end of 5‑year reasonable useful lifetime or earlier only for documented clinical need/change.

Document reason for replacement (end of RUL vs clinical change)
Replacements for misuse/abuse will be denied

Billing Rule

Noncovered Device/Service Triggers — Check Coding Table

Noncovered device/service triggers: Certain devices and CPT/HCPCS codes (eg, Zzoma positional device HCPCS E0190, specified palatal and experimental device codes, some surgical codes when criteria not met) are listed as not covered for indications in the policy. Verify coding against the policy’s coding tables and ensure medical necessity criteria are documented for covered surgical codes.

Zzoma positional device (E0190) listed as not medically necessary
Specific CPT/HCPCS/ICD‑10 codes in the coding section flagged as not covered when criteria not met

Denial Risk

ASV and Bilevel with Backup Rate — Investigational for OSA

ASV / bilevel with backup rate investigational: Adaptive servo‑ventilation (ASV) and bilevel devices with a backup rate feature are considered experimental/investigational for OSA (consistent with DME MAC guidance) and are not medically necessary for routine OSA treatment.

ASV/backup‑rate bilevel devices use (eg, VPAP Adapt) is investigational for OSA indications
Considered only per specific non‑OSA indications consistent with coverage rules

Denial Risk

Palatal Implants — Evidence Insufficiency and Denial Risk

Palatal implants — evidence insufficiency: Palatal implants (eg, Pillar system, other soft‑palate implants) have limited and inconsistent evidence; several technology assessments recommend against routine use. Coverage is unlikely without strong, case‑specific evidence; prior authorization and review recommended.

CADTH and NICE concluded inadequate evidence to support routine palatal implant use for OSA
Randomized trials show mixed/limited benefit and device‑related risks (eg, partial extrusion)

Denial Risk

Selection‑Related Exclusion Risks — Watch for Denial Triggers

Selection‑related exclusion risks: Device/surgical candidacy exclusions (eg, BMI thresholds, neuromuscular disease, severe cardiopulmonary disease, large tonsils, pacemaker considerations for some devices) identified in trials and device labeling may lead to denial if patient falls outside selection criteria.

Examples: historical UAS trial exclusions included BMI >32 (labeling updated over time); other exclusions include neuromuscular disease, hypoglossal palsy, severe pulmonary hypertension, recent MI
Check device labeling and trial criteria for current BMI and comorbidity cutoffs

Denial Risk

Contraindicating Conditions May Lead to Denial

Contraindicating conditions that may lead to denial: Documented complete concentric collapse of the velum on DISE, significant anatomic findings (eg, tonsil size 3–4 for some devices), active psychiatric disease, pregnancy, lack of ability to operate device programmer, and other contraindications per device labeling can render a patient ineligible for implantable neurostimulation or specific device use.

Absence of complete concentric collapse is required for UAS candidacy — presence may lead to denial
Document other anatomical or functional contraindications noted in device labeling

Denial Risk

Limited Evidence May Lead to Denial for Emerging Procedures/Devices

Evidence insufficiency risk for many pharyngeal surgeries and novel devices: Many pharyngeal surgeries, novel palatal expansion techniques, and emerging devices (tongue anchors, NightLase LAUP, EASE, Elevo, Slow Wave DS8) have limited high‑quality evidence; requests for coverage should include robust pre‑ and post‑operative objective metrics and may be subject to denial if evidence is insufficient.

Multi‑level surgery evidence often level 4 (case series) — careful selection and documentation needed
Emerging technologies frequently lack long‑term comparative data

Documentation Required

DISE and UAS Evaluation — Operational Note

DISE and UAS evaluation — operational note: DISE is part of UAS evaluation and should be documented using standardized descriptors (eg, VOTE). Inter‑rater variability exists; include DISE video/report in pre‑authorization materials when available.

Include DISE report/video and VOTE classification when requesting UAS coverage
Note potential variability in DISE interpretation and include supporting PSG/clinical data

Documentation Required

Device Indication and Evidence — Documentation Expectations

Device indication and evidence (Lunoa, positional devices, SPT, ULTepap): For positional devices and other new devices (Lunoa, SPT, ULTepap), document positional dependence, baseline PSG/WatchPAT metrics, device‑specific AHI cutoffs (eg, Lunoa non‑supine AHI <20), and patient adherence/response metrics. FDA clearance does not equate to robust long‑term effectiveness.

Document baseline non‑supine and supine AHI and device‑measured positional data where available
Provide short‑term objective outcomes and adherence data when seeking coverage

Denial Risk

Novel Interventions — Limited Evidence May Result in Denial

Limited evidence may lead to denial for novel interventions: For procedures such as EASE, elevoplasty/Elevo, NightLase LAUP, Slow Wave DS8, and other minimally invasive interventions, the current evidence base is limited and often retrospective or small‑scale; prior authorization with robust clinical justification is recommended and claims may be denied if evidence for effectiveness is not provided.

Provide peer‑reviewed outcomes, PSG changes, and safety data when requesting coverage for novel interventions
Expect medical review for small uncontrolled study–based justifications

Documentation Required

Hypoglossal Stimulation — Required Documentation

Hypoglossal stimulation documentation: For hypoglossal nerve stimulation/UAS requests, include age, BMI, PSG (AHI/ODI) within device timeframe, DISE findings (absence of complete concentric collapse), documentation of predominant obstructive events (<25% central/mixed), objective CPAP trial data showing failure or intolerance, and informed consent regarding device risks/benefits.

PSG within labeled timeframe (eg, historically 24 months) and device‑specified AHI/ODI limits
Document CPAP monitoring: failure (AHI remains elevated on CPAP) or intolerance (<4 hrs/night on ≥5 nights/week)

Documentation Required

CPAP Trial Monitoring — Objective Documentation Required

CPAP trial monitoring: Document objective CPAP adherence and effectiveness using compliance downloads (smart card, device reports). Adherence defined as ≥4 hours/night on ≥70% of nights over a consecutive 30‑day period (policy definition for continued use); UAS and other device trials require documentation of CPAP failure or intolerance per device criteria.

Include device compliance report showing hours/night and percent nights
For UAS: document CPAP failure (AHI above device threshold despite CPAP) or documented intolerance (<4 hrs/night on 5 nights/week)

Documentation Required

Required Outcome Measurements for Device/Surgical Interventions

Required outcome measurements: Authorizations and continued coverage decisions should include objective outcome measures when applicable — PSG AHI/ODI, oxygen desaturation index (ODI), Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), and device‑measured adherence. Provide baseline and follow‑up measures to demonstrate clinical benefit.

Common metrics: AHI, ODI, ESS, FOSQ, percent time <90% O2 saturation
Include pre‑ and post‑intervention PSGs or device‑measured outcomes where available

Prior Authorization

Pre‑Implantation Documentation Required

Required pre‑implantation documentation: For implantable devices (UAS, neurostimulators), submit pre‑implantation PSG, DISE report, CPAP trial documentation, BMI and comorbidity assessment, and any device‑specific screening results. Ensure documentation aligns with published trial inclusion/exclusion criteria and current FDA labeling.

Pre‑implant PSG and DISE (VOTE) required for UAS requests
Document prior CPAP trial and objective compliance/titration data

Documentation Required

Pre‑operative DISE and PSG — Documentation Expectations

Pre‑op DISE and PSG: When surgery or implant is being considered, include full PSG and DISE in the pre‑operative evaluation as used in pivotal studies. DISE should document the pattern and level(s) of collapse; PSG should provide baseline AHI/ODI and oxygenation metrics.

DISE and PSG reports improve selection and predict surgical outcomes
Use standardized scoring (VOTE) for DISE where possible

Documentation Required

Required Outcome Documentation for Surgical Expansion Procedures

Required clinical documentation for surgical expansion and other surgeries: For procedures such as palatopharyngoplasty, jaw realignment, EASE, glossectomy, and palatal expansion, include documentation of prior CPAP trials, objective baseline PSG, anatomic findings supporting surgery, surgical plan, and post‑operative PSG or objective outcome measures to support medical necessity.

Palatopharyngoplasty requires documented prior CPAP/AutoPAP attempt and intolerance/failure
Jaw realignment often requires multi‑disciplinary review and documentation that less‑invasive options failed

Documentation Required

Required Clinical Documentation for Testing

Required clinical documentation for testing: For diagnostic testing (home or facility PSG/HSAT), document clinical features (eg, ESS >10, BMI >30, witnessed apneas, daytime sleepiness while driving) that meet indications for testing, and ensure test type and scoring meet policy definitions. Repeat testing for equipment replacement alone is not medically necessary unless other policy criteria are met.

Appendix indications: ESS ≥10, BMI >30, witnessed apnea, excessive sleepiness while driving
Repeat sleep testing for replacement CPAP equipment is not medically necessary absent other indications

Step Therapy

Step Therapy — CPAP First‑Line; Prior CPAP Trial Required Before Surgery/Alternatives

Step requirement before palatopharyngoplasty and require prior CPAP trial for alternatives: Surgical interventions (eg, UPPP/palatopharyngoplasty) and alternatives (oral appliances, surgery, neurostimulation) are expected to follow a stepwise approach with CPAP as first‑line; document attempted CPAP (titration, mask adjustments) and objective failure or intolerance before elective pharyngeal surgery.

Document CPAP attempts, mask/interface optimization, and objective adherence/response before surgery
CPAP is first‑line; bilevel/other modalities reserved as second‑line when CPAP intolerant or ineffective

Step Therapy

CPAP Trial Required; UAS Considered Second‑Line

Require prior trial/intolerance of CPAP; UAS as second‑line after CPAP: Upper airway stimulation and many surgical/device alternatives are second‑line therapies for patients who fail or are intolerant of CPAP. Document objective CPAP failure (persistently elevated AHI on CPAP) or intolerance (insufficient usage) before considering UAS or other invasive options.

UAS is indicated as second‑line for patients unable or unwilling to use CPAP with demonstrated failure/intolerance
Provide objective CPAP compliance/download data

Step Therapy

Stepwise Management — Neurostimulation After Less‑Invasive Options

Step therapy consideration for neurostimulation vs less‑invasive options: Consider less‑invasive options (CPAP optimization, oral appliances, positional therapy) before neurostimulation when clinically appropriate. For neurostimulation, ensure prior steps are documented and clinical rationale for progression to implantable therapy is clear.

Document trials of less‑invasive therapies and reasons for progression to implanted neurostimulation
Include objective outcome measures from prior therapies

Note

No Universal Step Therapy Narrative for All Novel Devices (Operational Note)

No explicit step therapy requirements provided in this excerpt for some novel devices: While the policy emphasizes CPAP first‑line and documents stepwise management for many interventions, it does not lay out uniform mandatory step therapy sequences for all novel devices; use clinical judgment and payer PA rules when sequencing therapies.

Check payer‑specific step therapy or PA policies for device sequencing
Document clinical rationale when deviating from typical stepwise approach

Step Therapy

Stepwise Management Before Novel Interventions — Documentation Recommended

Stepwise management before novel interventions: For emerging technologies and novel interventions (eg, elevoplasty, TES/TENS, EASE, Slow Wave DS8), document prior conventional therapy attempts, objective metrics of failure or intolerance, and provide study evidence or registries where available to support medical necessity.

Provide evidence of prior CPAP/oral appliance/positional therapy trials where applicable
Include prospective outcome data or trial evidence when requesting coverage for novel interventions

Hypopneas contribute to both AHI and RDI depending on study type and reporting method

AHI definition

AHI definitionAverage number of apneas and hypopneas per hour of sleep (reported in Type I or Type II studies)

Reporting limitationAHI requires measurement of sleep time (available only in Type I/II studies)

Role in policyAHI thresholds drive coverage decisions for PAP, oral appliances, and other therapies

RDI definition

RDI definitionEpisodes of apnea and hypopnea per hour of recording (reported in Type III, Type IV, and other home studies)

Differences from AHIRDI is based on recording time rather than sleep time and is used for home and limited channel studies

Policy applicationRDI thresholds are acceptable for coverage determinations when derived from appropriate device types meeting sensor requirements

Intolerance to CPAP/AutoPAP definition

CPAP intolerance examplesIncludes claustrophobia, difficulty tolerating pressure, inability to sleep with device, intolerance of nasal or mouth interface, nasal irritation, or repeated unintentional removal of CPAP during sleep

Documentation requirementMedical records must document attempted CPAP/AutoPAP and reasons for intolerance prior to surgery (eg, UPPP)

Implication for alternativesCPAP intolerance supports consideration of alternatives (BiPAP, oral appliances, surgery) when documented

Type I–IV diagnostic study types

Type I (NPSG)Attended in‑facility polysomnography with ≥7 parameters and technician attendance (comprehensive standard overnight PSG)

Type IIComprehensive portable monitor with minimum of 7 channels (EEG, EOG, EMG, ECG/HR, airflow, respiratory effort, oximetry)

Type III and IVType III: ≥4 channels including ventilation/airflow, HR/ECG, oximetry; Type IV: limited monitors (IV(A): ≥3 bioparameters; IV(B): 1–2 parameters such as overnight oximetry)

Clinical criteria suggesting increased risk for OSA

Clinical feature set for increased OSA riskExcessive daytime sleepiness plus at least two of: habitual loud snoring, witnessed apnea/gasping/choking, or diagnosed hypertension

Additional risk factorsBMI ≥30, large neck circumference, male sex, post‑menopausal female, and hypertension increase pretest probability

Policy actionPatients meeting these criteria should be evaluated with PSG or an adequate home sleep study

OPAP definition

OPAP definitionOral Pressure Appliance: custom intra‑oral device connected to PAP hose that positions the lower jaw forward and delivers airflow/pressure to the oropharynx

Usage noteUsed in place of a standard nasal mask; no peer‑reviewed studies available comparing effectiveness to standard nasal masks at time of policy

Clinical implicationConsidered only on exception basis for members unable to tolerate standard interfaces

ASV definition

ASV definitionAdaptive servo‑ventilation: a bilevel PAP device with a backup rate and automatic minute‑ventilation targeting that adjusts breath‑by‑breath

Evidence stanceStudied primarily for central apnea/Cheyne‑Stokes respiration; considered experimental/investigational for OSA per DME MAC policy

Clinical cautionUse in OSA may be denied due to investigational status in this indication

EPAP definition

EPAP definitionExpiratory Positive Airway Pressure: a nasal device imposing expiratory resistance via one‑way valves to create positive pressure during exhalation

Clinical evidenceRandomized and cohort studies show reductions in AHI and ESS in subsets of patients with generally high self‑reported adherence

Indication noteMay be considered for CPAP‑intolerant patients when objective PSG improvement is demonstrated

TAP definition

TAP definitionTranspalatal advancement pharyngoplasty: surgical advancement of the palate (without excision of soft palate) to widen retro‑palatal airway

Data statusVery limited published outcomes data; used alone or with tongue‑base procedures in selected patients

Clinical implicationLarger studies needed to establish safety and effectiveness compared to established palatal techniques

MSLT definition

MSLT definitionMultiple Sleep Latency Test: daytime nap test evaluating sleep latency; sleep latency <6 minutes considered clinically significant

Role in OSANot routinely indicated for initial OSA diagnosis or CPAP response assessment; mainly used for narcolepsy evaluation

Testing contextTypically administered after overnight PSG when indicated clinically

SleepStrip scoring

SleepStrip scoringDisposable lip‑mounted flow detector results map approximately to AHI ranges: 0 (no apneas), 1 (AHI 15–24), 2 (AHI 25–39), 3 (AHI >40), E (error)

Use caseUsed for screening; categorical output approximates laboratory AHI ranges

LimitationsNot a substitute for PSG for definitive diagnosis or treatment decisions per policy

Oral pressure therapy (OPT) definition

OPT definitionOral Pressure Therapy (OPT, e.g., Winx®): a non‑invasive system applying oral negative pressure to stabilize the upper airway

Clinical trial evidenceShort‑term multicenter trials showed subgroup clinical responders (example responder: treatment AHI ≤10 and ≤50% of control)

Coverage implicationConsider only when PSG trial demonstrates response and patient cannot tolerate CPAP

Acoustic/tracheal sound analysis definition

Acoustic/tracheal sound analysis definitionMethods using recorded respiratory sounds to estimate sleep/wake state and respiratory flow; validated against PSG in preliminary studies

Accuracy limitationsReported epoch‑by‑epoch sleep/wake accuracy ~82% in a validation cohort; quantitative sleep metrics have notable error margins

Clinical statusClinical effectiveness requires further validation before replacing PSG for diagnostic decisions

Upper-airway stimulation (UAS) definition

UAS definitionUpper‑airway stimulation (hypoglossal nerve stimulation): implanted system stimulating hypoglossal nerve to activate tongue protrusor muscles and maintain airway patency during sleep

ComponentsImplantable pulse generator, leads/array, sensing/respiratory sensor electrode, and external programmer per device system

Indication contextUsed as a second‑line therapy for selected patients intolerant of CPAP with specified AHI/BMI and endoscopic findings per FDA labeling

FDA eligibility for UAS (historical/current)

Initial FDA eligibility (historical)Age ≥22 years; AHI 20–65 events/hour; predominantly obstructive events (<25% central/mixed); CPAP failure or intolerance; no complete concentric velopharyngeal collapse; BMI generally ≤32

2017 FDA expansionAHI lower limit expanded to 15 events/hour (March 2017)

2023 FDA expansion and current labelingUpper AHI limit increased to ≤100 events/hour and recommended BMI upper limit increased to 40 kg/m2 (June 2023); device MR‑conditional labeling updates noted

Partial epiglottidectomy definition

Partial epiglottidectomy definitionEndoscopic resection of part of the epiglottis (often with CO2 laser) to relieve posterior displacement or prolapse contributing to hypopharyngeal obstruction

Indication noteConsidered in selected patients with epiglottic prolapse or obstruction; evidence limited to small series

Outcome variabilityCase series report variable PSG improvement (eg, Golz et al showed PSG improvement in 85% in small cohort)

Genioplasty / GTA definition

Genioplasty / GTA definitionSurgical advancement of the genial tubercle and/or chin (genioplasty; genial tubercle advancement) to enlarge the retroglossal airway

Reported effectSystematic reviews report relative AHI reductions (eg, standard genioplasty ~43.8% reduction; GTA/GTA‑HS show larger reductions in some series)

Evidence noteNumber of studies limited; procedures remain an area for additional research

Lateral pharyngoplasty definition

Lateral pharyngoplasty definitionModified palatal surgery removing tissue from the lateral free margin of the soft palate to alter lateral pharyngeal wall properties

Comparative dataRandomized trial reported greater reductions in AHI and symptoms versus UPPP in a small cohort

Evidence caveatFurther larger studies needed to confirm findings and durability

DISE definition

DISE definitionDrug‑induced sleep endoscopy: flexible fiberoptic endoscopic exam of upper airway under sedative‑induced sleep to identify sites and patterns of obstruction (often recorded with VOTE classification)

Clinical useUsed to guide surgical planning and is required as part of UAS candidacy evaluation per policy when indicated

LimitationsSubjective with inter‑rater variability; standardization and corroboration recommended

RCMP definition

RCMP definitionRemotely Controlled Mandibular Positioner: device used during single‑night titration to progressively protrude the mandible under polysomnographic observation to determine effective protrusive position predicting oral appliance success

Predictive roleRCMP titration has been associated with predicting success of mandibular advancement oral appliances in studies

Evidence caveatStudy heterogeneity limits generalizability, but it may be a promising predictive tool

Positional OSA (POSA) definition

Positional OSA (POSA) definitionOSA in which frequency/duration of apneas are influenced by body position, often higher AHI in supine position; candidates for positional therapy when non‑supine AHI meets device criteria

Device exampleLunoa System cleared for adults with positional OSA and non‑supine AHI <20 (device‑specific indication)

Clinical implicationPositional therapy may be reasonable for strictly positional OSA or when CPAP adherence is poor; inferior to CPAP for AHI reduction overall

Robotic tongue-base reduction / midline glossectomy definition

Robotic tongue‑base reduction / midline glossectomy definitionSurgical approaches (robotic or endoscopic) to reduce tongue‑base volume aiming to improve airway patency and reduce AHI

Reported outcomesRetrospective series report AHI improvements and surgical success rates varying by technique and patient selection (robotic often higher success)

ComplicationsReported complications include bleeding and transient dysphagia; evidence limited by retrospective designs

Biomarker findings summary

Biomarker summaryMeta‑analyses report higher circulating IL‑6, TNF‑α, CRP/hs‑CRP, and MDA concentrations in adults with OSA versus controls, with some markers correlating with disease severity

Heterogeneity noteSubstantial heterogeneity and potential publication bias exist across biomarker studies; clinical utility as diagnostic biomarkers remains unproven

Research implicationFurther standardized studies needed before routine clinical use of these biomarkers for diagnosis or management

EASE / MARPE definitions

EASE definitionEndoscopically‑Assisted Surgical Expansion (EASE): outpatient surgical maxillary expansion technique reported in small retrospective series to widen nasal floor and improve airway

MARPE definitionMiniscrew‑Assisted Rapid Palatal Expansion (MARPE): palatal expansion technique using miniscrews to increase maxillary width and potentially improve airway measures

Evidence noteBoth approaches currently supported by small cohorts/early reports; UpToDate does not list palatal expansion as standard adult OSA management

Neurostimulation approaches defined

Neurostimulation approaches overviewIncludes invasive hypoglossal nerve stimulation (HNS/UAS), transcutaneous electrical stimulation (TES/TENS), and ansa cervicalis stimulation (ACS) as emerging or established neurostimulation strategies

HNS statusHNS is an established invasive alternative for selected CPAP‑intolerant patients with robust trial evidence (eg, STAR trial)

TES/ACS statusTranscutaneous and ansa cervicalis stimulation are investigational or early‑phase with promising physiologic data requiring further clinical trials

eXciteOSA device definition

eXciteOSA definitionRemovable daytime intraoral neuromuscular stimulation device cleared by FDA for adults ≥18 with mild OSA (AHI 5–15) and snoring; used 20 minutes once daily for 6 weeks

Indication limitsFDA clearance restricted to mild OSA (AHI 5–15) and snoring; trials excluded higher AHI and higher BMI ranges

Coverage considerationPolicy suggests coverage decisions align with FDA clearance and trial selection criteria

Natural sleep endoscopy (NSE) definition

NSE definitionNatural Sleep Endoscopy: endoscopic visualization of the upper airway during natural sleep to assess sites/patterns of collapse; comparative evidence vs DISE limited

Findings summarySoft palate most frequent site of obstruction; standardization of classification recommended

Research roleUseful in research and validation of novel diagnostics but not yet a standardized clinical triage tool compared to DISE

AHI glossary entry

AHI glossary entryApnea‑Hypopnea Index (AHI): average number of episodes of apnea and hypopnea per hour of sleep; scale used to grade OSA severity

Usage noteReported in Type I/II studies where sleep time is measurable; informs coverage thresholds

Relation to severityCommonly used severity categories (mild/moderate/severe) derived from AHI ranges in clinical practice

PAP abbreviations (CPAP/APAP/BiPAP) glossary

PAP abbreviationsCPAP: continuous positive airway pressure; APAP: auto‑adjusting positive airway pressure; BiPAP: bilevel positive airway pressure (different inspiratory/expiratory pressures)

Clinical implicationCPAP is first‑line therapy; APAP may be used as auto‑titrating option; BiPAP used for CPAP intolerance or specific comorbidities

Device reportingPAP device type and settings should be documented in clinical records and prior authorization requests as applicable

Epworth Sleepiness Scale (ESS) definition

Epworth Sleepiness Scale (ESS) definitionQuestionnaire assessing likelihood of falling asleep in common situations; total score >10 considered abnormal

Use in policyESS >10 is an accepted criterion to justify diagnostic testing for OSA in adults per policy appendix

ScoringEight items scored 0–3 and summed; total >10 abnormal

Excessive daytime sleepiness (EDS) definition

EDS definitionExcessive daytime sleepiness (EDS): inability to maintain wakefulness and alertness with unintentional sleep occurring almost daily for ≥3 months (ICSD‑3/AASM)

Clinical roleEDS plus other features (eg, BMI >30, loud snoring, witnessed apneas) indicates testing is medically necessary per policy

Objective measuresMSLT sleep latency <6 minutes is clinically significant but MSLT not routine for OSA evaluation

Monitoring device Types I–IV definitions

Monitoring device Type IType I: in‑lab polysomnography with ≥7 parameters and technician attendance (comprehensive standard overnight PSG)

Monitoring device Type IIType II: comprehensive portable monitor with ≥7 parameters (EEG, EOG, EMG, ECG/HR, airflow, respiratory effort, oximetry)

Monitoring device Type III/IVType III: ≥4 channels including ventilation/airflow, HR/ECG, oximetry; Type IV(A): ≥3 bioparameters; Type IV(B): 1–2 parameters (eg, overnight oximetry)